Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of Haemophilia A. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Industry, Sector and Symbol
Industry Tobacco products
Sub-IndustryN/A
SectorMedical
Phone31-71-524-7400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$101.24 million
Profitability
Miscellaneous
Employees150
OptionableNot Optionable
Pharming Group (OTCMKTS:PHGUF) Frequently Asked Questions
What is Pharming Group's stock symbol?
Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."
How were Pharming Group's earnings last quarter?
Pharming Group (OTCMKTS:PHGUF) released its quarterly earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a negative net margin of 36.30% and a negative return on equity of 176.01%. View Pharming Group's Earnings History.
When is Pharming Group's next earnings date?
What is the consensus analysts' recommendation for Pharming Group?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pharming Group.
Has Pharming Group been receiving favorable news coverage?
Press coverage about PHGUF stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pharming Group earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are some of Pharming Group's key competitors?
Who are Pharming Group's key executives?
Pharming Group's management team includes the folowing people:
- Dr. Sijmen de Vries M.D., MBA, Chairman of Management Board & CEO (Age 59)
- Mr. Robin Wright BA (Oxon), FCA., CFO & Member of Management Board (Age 54)
- Dr. Bruno M. L Giannetti, COO & Member of Management Board (Age 66)
- Dr. Pericles Calias, Chief Scientific Officer
- Ms. Anne-Marie de Groot, Sr. VP of Organisational Devel. (Age 37)
How do I buy shares of Pharming Group?
Shares of PHGUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pharming Group's stock price today?
One share of PHGUF stock can currently be purchased for approximately $0.97.
How big of a company is Pharming Group?
Pharming Group has a market capitalization of $509.53 million and generates $101.24 million in revenue each year. The biotechnology company earns $-90,370,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Pharming Group employs 150 workers across the globe.
What is Pharming Group's official website?
How can I contact Pharming Group?
Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The biotechnology company can be reached via phone at 31-71-524-7400 or via email at [email protected]
MarketBeat Community Rating for Pharming Group (OTCMKTS PHGUF)
MarketBeat's community ratings are surveys of what our community members think about Pharming Group and other stocks. Vote "Outperform" if you believe PHGUF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHGUF will underperform the S&P 500 over the long term. You may vote once every thirty days.
